Shockwave Medical, Inc. owns U.S. Patent No. 8,956,371, which describes a shockwave balloon catheter system for treating atherosclerosis through intravascular lithotripsy. Cardiovascular Systems, Inc. challenged this patent in 2018, arguing it was obvious based on prior art, including Levy's methods of using laser pulses and the applicant admitted prior art. The Patent Trial and Appeal Board found claims 1-4 and 6-17 unpatentable, while claim 5 remained intact. AAPA's classification as prior art was influenced by subsequent guidance from the U.S. Patent and Trademark Office.
Shockwave owns U.S. Patent No. 8,956,371 directed to treating atherosclerosis with an intravascular lithotripsy system using shockwaves to break up calcified plaque.
CSI filed an inter partes review petition challenging the '371 patent, claiming it was obvious over prior art, including Levy and AAPA references.
The Patent Trial and Appeal Board found multiple claims of the '371 patent, except claim 5, unpatentable as obvious based on CSI's evidence.
The Board's treatment of the AAPA as prior art under 35 U.S.C. § 311(b) changed after guidance from the U.S. Patent Office.
#patent-litigation #intravenous-lithotripsy #obviousness #shockwave-technology #cardiovascular-devices
Collection
[
|
...
]